Tumour Lysis Syndrome in Paediatric Oncology: Pathophysiology, Risk Assessment, Prevention and Management
NIGERIAN JOURNAL OF PAEDIATRICS · 30.09.2026 · 53 (3) · ES021-ES024
DOI: 10.63270/njp.v53i3.2000089 ↗Kurz gefasst
Fachartikel in der Zeitschrift NIGERIAN JOURNAL OF PAEDIATRICS, online erschienen am 30.09.2026. Verfasst von Motunrayo Adekunle.
Abstract (Originalsprache)
Tumour Lysis Syndrome (TLS) is a life-threatening metabolic emergency caused by the rapid destruction of tumour cells, either spontaneously or following cancer treatment. It is mostly seen in malignancies with a high tumour burden, rapid cell proliferation, and high sensitivity to treatment. TLS may occur after chemotherapy, immunotherapy, targeted therapy, and, less commonly, radiotherapy. Mortality rates can be as high as 21%, particularly in resource-limited settings.
Zitieren
APA
Adekunle, M. (2026). Tumour Lysis Syndrome in Paediatric Oncology: Pathophysiology, Risk Assessment, Prevention and Management. NIGERIAN JOURNAL OF PAEDIATRICS, 53(3), ES021-ES024. https://doi.org/10.63270/njp.v53i3.2000089
Vancouver
Adekunle M. Tumour Lysis Syndrome in Paediatric Oncology: Pathophysiology, Risk Assessment, Prevention and Management. NIGERIAN JOURNAL OF PAEDIATRICS. 2026;53(3):ES021-ES024. doi:10.63270/njp.v53i3.2000089
BibTeX
@article{Adekunle2026,
author = {Adekunle, Motunrayo},
title = {Tumour Lysis Syndrome in Paediatric Oncology: Pathophysiology, Risk Assessment, Prevention and Management},
journal = {NIGERIAN JOURNAL OF PAEDIATRICS},
year = {2026},
volume = {53},
number = {3},
pages = {ES021--ES024},
doi = {10.63270/njp.v53i3.2000089}
}
EUVIMED